SCHEDULE: Goldman Sachs Discloses 2.9% Stake in Indivior Pharma

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have reported a 2.9% beneficial ownership stake in Indivior Pharmaceuticals, Inc. as of December 31, 2025.

Summary

• The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, jointly reported beneficial ownership of 3,592,430.80 shares of Indivior Pharmaceuticals, Inc. common stock.
• This ownership represents 2.9% of the class of securities.
• The reporting persons hold shared voting power over 3,592,395.80 shares and shared dispositive power over 3,592,430.80 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Indivior Pharmaceuticals, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development. While a Schedule 13G is a routine disclosure, the presence of a significant institutional investor like Goldman Sachs holding a 2.9% stake can be seen as a positive signal of confidence in Indivior Pharmaceuticals, Inc., though it does not provide new operational or financial performance data.

Positives

• A significant institutional investor like Goldman Sachs holding a 2.9% stake can be viewed as a vote of confidence in Indivior Pharmaceuticals, Inc.

Negatives

• The filing itself does not present any negative information regarding Indivior Pharmaceuticals, Inc.

Risks

• The filing does not detail specific risks related to Indivior Pharmaceuticals, Inc.'s operations or financial health, as it is a disclosure of ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the disclosure of a 2.9% stake by a major financial institution like Goldman Sachs in Indivior Pharmaceuticals, Inc. signals continued institutional interest in the pharmaceutical sector, particularly in companies like Indivior. This type of institutional holding can often be interpreted by the market as a positive indicator of a company's long-term prospects or stability, especially within the competitive and regulated pharmaceutical industry.

Stakeholder Impact

• Shareholders: May view Goldman Sachs' stake as a positive signal, potentially increasing confidence and attracting further institutional investment.
• Employees, Customers, Suppliers, Creditors: No direct impact from this ownership disclosure.

Key Dates

Recommendation

While the disclosure of a 2.9% stake by a prominent institution like Goldman Sachs in Indivior Pharmaceuticals, Inc. is a positive signal of institutional interest and confidence, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial performance data. Therefore, without additional fundamental analysis or new company-specific news, a 'hold' recommendation is appropriate, acknowledging the institutional backing while awaiting further catalysts for a stronger directional call.

Keywords

Indivior Pharmaceuticals, Goldman Sachs, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, SEC Filing